Welcome to our dedicated page for Mindset Pharma news (Ticker: MSSTF), a resource for investors and traders seeking the latest updates and insights on Mindset Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mindset Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mindset Pharma's position in the market.
Mindset Pharma Inc. (OTCQB: MSSTF), a leader in developing next-generation psychedelic medicines, will participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021. CEO James Lanthier will join the Future of Mental Healthcare panel at 2:30 p.m. ET, with his corporate presentation available on-demand from 7:00 a.m. ET. Mindset focuses on drug discovery to address neurological and psychiatric disorders, creating optimized psychedelic compounds and innovating psilocybin synthesis. More details can be found on their website.
Mindset Pharma Inc. (OTCQB: MSSTF) presented preclinical data on its psilocybin analog, MSP-1014, at the Society for Neuroscience meeting. The presentation highlighted the pharmacokinetic and pharmacodynamic properties linked to the 5-HT2A receptor, showcasing the drug's potential for treatment-resistant depression and end-of-life cancer angst. The data strengthens the company’s research credibility within the scientific community. MSP-1014 aims to address significant unmet medical needs in neurological disorders, marking a crucial step towards human clinical trials.
Mindset Pharma Inc. (OTCQB: MSSTF) announced significant progress in its drug development pipeline, focusing on next-generation psychedelic medicines aimed at mental health disorders. The company has moved its lead candidate, MSP-1014, a psilocybin-based compound, into IND-enabling studies, targeting treatment-resistant depression and end-of-life cancer angst. It has expanded its patent portfolio with eight provisional applications and provided preclinical evidence of enhanced safety and efficacy across four drug families. Fiscal year-end cash was approximately $6.6 million, indicating a solid capital position for growth.
Mindset Pharma (OTCQB: MSSTF) announced its participation in Microdose’s Wonderland: Miami on November 8-9, 2021. The company's CEO, James Lanthier, and CSO, Joseph Araujo, will present Beyond Psilocybin: New Frontiers in Psychedelic Drug Design at 12:45 p.m. ET on November 8. Mindset Pharma focuses on developing next-generation psychedelic medicines addressing neurological and psychiatric disorders. For more details, visit www.mindsetpharma.com.
Mindset Pharma Inc. (OTCQB: MSSTF) has advanced its psychedelic medicine research through its COPE program with InterVivo Solutions. This initiative established standard pharmacokinetic data and protocols for LSD, psilocybin, and 5-MeO-DMT. CEO James Lanthier highlighted the potential market opportunity in providing benchmarking data against first-generation compounds. The program aims to create a comprehensive psychedelics benchmark reference data set, aiding the development of next-generation drugs for neurological and psychiatric disorders.
Mindset Pharma Inc. (OTCQB: MSSTF) announced that its CEO, James Lanthier, will participate in the KCSA Psychedelics Investor Conference on October 13-14, 2021. Mr. Lanthier will present live on October 14 at 10:00 a.m. ET. Mindset Pharma focuses on developing next-generation psychedelic medicines for neurological and psychiatric disorders. The conference aims to facilitate direct interaction between publicly-traded companies and investors, enhancing engagement in an innovative format.
Mindset Pharma (OTCQB: MSSTF) announced positive preclinical results for its compounds MSP-4019 and MSP-4020, demonstrating efficacy and an improved safety profile compared to 5-MeO-DMT. Utilizing conjugate amplification technology, these next-generation psychedelic medicines aim to address mental health disorders effectively. The compounds showed no signs of 5-HT syndrome, a concern with earlier drugs. The company plans to advance these candidates into clinical trials following further validation.
Mindset Pharma (OTCQB: MSSTF) has been included in the AdvisorShares Psychedelics ETF (PSIL), which focuses on investments in the burgeoning psychedelic drugs sector. This actively managed ETF primarily invests in companies that generate significant revenue from psychedelic drugs. CEO James Lanthier expressed enthusiasm over this inclusion, viewing it as a positive advancement for both the company and the broader industry. The announcement signifies growing recognition of Mindset as a leader in the psychedelic medicine market, particularly for neurological and psychiatric disorders.
Mindset Pharma Inc. (OTCQB: MSSTF) announced preclinical proof-of-concept data showcasing its candidate MSP-4018, demonstrating superior efficacy and safety compared to 5-MeO-DMT. The company is optimistic about advancing to human clinical trials due to this promising data. Observations indicated that MSP-4018 maintained locomotor activity and rearing behavior across various doses, contrasting the declines noted in 5-MeO-DMT. Mindset's proprietary Family 4 compounds highlight a commitment to developing optimized psychedelic medicines for neurological and psychiatric disorders.
Mindset Pharma has reported promising results for its lead candidate, MSP-1014, in a drug discrimination assay, demonstrating effects comparable to psilocybin. The study identified an effective dosage of 0.6 mg/kg with no adverse effects at doses up to 2 mg/kg. This further confirms MSP-1014 as a viable second-generation psychedelic drug. The company aims to continue preclinical studies and prepare for human clinical trials. The results underscore Mindset's commitment to developing next-generation psychedelic medicines for neurological and psychiatric disorders.